Advertisement

Intensive Care Medicine

, Volume 45, Issue 2, pp 159–171 | Cite as

Challenges in severe community-acquired pneumonia: a point-of-view review

  • Antoni TorresEmail author
  • James D. Chalmers
  • Charles S. Dela Cruz
  • Cristina Dominedò
  • Marin Kollef
  • Ignacio Martin-Loeches
  • Michael Niederman
  • Richard G. Wunderink
Review

Abstract

Purpose

Severe community-acquired pneumonia (SCAP) is still associated with substantial morbidity and mortality. In this point-of-view review paper, a group of experts discuss the main controversies in SCAP: the role of severity scores to guide patient settings of care and empiric antibiotic therapy; the emergence of pathogens outside the core microorganisms of CAP; viral SCAP; the best empirical treatment; septic shock as the most lethal complication; and the need for new antibiotics.

Methods

For all topics, the authors describe current controversies and evidence and provide recommendations and suggestions for future research. Evidence was based on meta-analyses, most recent RCTs and recent interventional or observational studies. Recommendations were reached by consensus of all the authors.

Results and conclusions

The IDSA/ATS criteria remain the most pragmatic tool to predict ICU admission. The authors recommend a combination of a beta-lactam/beta-lactamase inhibitor or a third G cephalosporin plus a macrolide in most SCAP patients, and to empirically cover PES (P. aeruginosa, extended spectrum beta-lactamase producing Enterobacteriaceae, methicillin-resistant S. aureus) pathogens when at least two specific risk factors are present. In patients with influenza CAP, the authors recommend the use of oseltamivir and avoidance of the use of steroids. Corticosteroids can be used in case of refractory shock and high systemic inflammatory response.

Keywords

Severe community-acquired pneumonia Scoring systems Multidrug resistance Viral pneumonia Antibiotics Septic shock 

Notes

Compliance with ethical standards

Conflicts of interest

Professor Torres is consultant for Pfizer, Bayer, Roche, MSD, Polyphor. Professor Chalmers reports grants and personal fees from Glaxosmithkline, grants and personal fees from Boehringer-Ingelheim, grants from Astrazeneca, grants and personal fees from Pfizer, grants and personal fees from Bayer Healthcare, grants and personal fees from Grifols, personal fees from Napp, personal fees from Aradigm corporation, grants and personal fees from Insmed, outside the submitted work. Professor Dela Cruz declares no conflict of interest. Doctor Dominedò declares no conflict of interest. Professor Kollef was supported by the Barnes-Jewish Hospital Foundation. Doctor Martin-Loeches declares no conflict of interest. Professor Niederman is consultant for Pfizer, Merck, Paratek and Melinta. Professor Wunderink is consultant for Nabriva, Melinta, bioMerieux, Curetis, Genmark, Accelerate.

Ethical approval

An approval by an ethics committee was not applicable.

References

  1. 1.
    Laporte L, Hermetet C, Jouan Y, Gaborit C, Rouve E, Shea KM, Si-Tahar M, Dequin PF, Grammatico-Guillon L, Guillon A (2018) Ten-year trends in intensive care admissions for respiratory infections in the elderly. Ann Intensive Care 8:84CrossRefGoogle Scholar
  2. 2.
    Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, Chappell JD, Qi C, Hart EM, Carroll F, Trabue C, Donnelly HK, Williams DJ, Zhu Y, Arnold SR, Ampofo K, Waterer GW, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, McCullers JA, Pavia AT, Edwards KM, Finelli L (2015) Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 373:415–427CrossRefGoogle Scholar
  3. 3.
    Cilloniz C, Dominedo C, Garcia-Vidal C, Torres A (2018) Community-acquired pneumonia as an emergency condition. Curr Opin Crit Care 24:531–539Google Scholar
  4. 4.
    Montull B, Menendez R, Torres A, Reyes S, Mendez R, Zalacain R, Capelastegui A, Rajas O, Borderias L, Martin-Villasclaras J, Bello S, Alfageme I, Rodriguez de Castro F, Rello J, Molinos L, Ruiz-Manzano J (2016) Predictors of severe sepsis among patients hospitalized for community-acquired pneumonia. PLoS ONE 11:e0145929CrossRefGoogle Scholar
  5. 5.
    Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG (2006) Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care 10(Suppl 2):S1CrossRefGoogle Scholar
  6. 6.
    Ranzani OT, Prina E, Menendez R, Ceccato A, Cilloniz C, Mendez R, Gabarrus A, Barbeta E, Bassi GL, Ferrer M, Torres A (2017) New sepsis definition (sepsis-3) and community-acquired pneumonia mortality. A validation and clinical decision-making study. Am J Respir Crit Care Med 196:1287–1297CrossRefGoogle Scholar
  7. 7.
    Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O’Brien KL, Andreo F, Beovic B, Blanco S, Boersma WG, Boulware DR, Butler JC, Carratala J, Chang FY, Charles PG, Diaz AA, Dominguez J, Ehara N, Endeman H, Falco V, Falguera M, Fukushima K, Garcia-Vidal C, Genne D, Guchev IA, Gutierrez F, Hernes SS, Hoepelman AI, Hohenthal U, Johansson N, Kolek V, Kozlov RS, Lauderdale TL, Marekovic I, Masia M, Matta MA, Miro O, Murdoch DR, Nuermberger E, Paolini R, Perello R, Snijders D, Plecko V, Sorde R, Stralin K, van der Eerden MM, Vila-Corcoles A, Watt JP (2013) Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE 8:e60273CrossRefGoogle Scholar
  8. 8.
    Cilloniz C, Gabarrus A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J, Niederman MS, Torres A (2016) Community-acquired pneumonia due to multidrug- and non-multidrug-resistant pseudomonas aeruginosa. Chest 150:415–425CrossRefGoogle Scholar
  9. 9.
    Garnacho-Montero J, Barrero-Garcia I, Gomez-Prieto MG, Martin-Loeches I (2018) Severe community-acquired pneumonia: current management and future therapeutic alternatives. Expert Rev Anti Infect Ther 16:667–677CrossRefGoogle Scholar
  10. 10.
    Pereira JM, Goncalves-Pereira J, Ribeiro O, Baptista JP, Froes F, Paiva JA (2018) Impact of antibiotic therapy in severe community-acquired pneumonia: data from the Infauci study. J Crit Care 43:183–189CrossRefGoogle Scholar
  11. 11.
    Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, Boersma WG, Compaijen CJ, van der Wall E, Prins JM, Oosterheert JJ, Bonten MJ (2015) Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 372:1312–1323CrossRefGoogle Scholar
  12. 12.
    Lee JH, Kim HJ, Kim YH (2017) Is beta-lactam plus macrolide more effective than beta-lactam plus fluoroquinolone among patients with severe community-acquired pneumonia?: a systemic review and meta-analysis. J Korean Med Sci 32:77–84CrossRefGoogle Scholar
  13. 13.
    Prina E, Ranzani OT, Polverino E, Cilloniz C, Ferrer M, Fernandez L, Puig de la Bellacasa J, Menendez R, Mensa J, Torres A (2015) Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc 12:153–160CrossRefGoogle Scholar
  14. 14.
    Waterer G (2017) Severity scores and community-acquired pneumonia. Time to move forward. Am J Respir Crit Care Med 196:1236–1238CrossRefGoogle Scholar
  15. 15.
    Chalmers JD, Mandal P, Singanayagam A, Akram AR, Choudhury G, Short PM, Hill AT (2011) Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 37:1409–1420CrossRefGoogle Scholar
  16. 16.
    Waterer GW, Self WH, Courtney DM, Grijalva CG, Balk RA, Girard TD, Fakhran SS, Trabue C, McNabb P, Anderson EJ, Williams DJ, Bramley AM, Jain S, Edwards KM, Wunderink RG (2018) In-hospital deaths among adults with community-acquired pneumonia. Chest 154:628–635CrossRefGoogle Scholar
  17. 17.
    Chalmers JD, Taylor JK, Mandal P, Choudhury G, Singanayagam A, Akram AR, Hill AT (2011) Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis 53:503–511CrossRefGoogle Scholar
  18. 18.
    Charles PG, Davis JS, Grayson ML (2009) Rocket science and the Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) guidelines for severe community-acquired pneumonia. Clin Infect Dis 48:1796 (author reply 1796–1797) CrossRefGoogle Scholar
  19. 19.
    Wunsch H, Angus DC, Harrison DA, Linde-Zwirble WT, Rowan KM (2011) Comparison of medical admissions to intensive care units in the United States and United Kingdom. Am J Respir Crit Care Med 183:1666–1673CrossRefGoogle Scholar
  20. 20.
    Lim HF, Phua J, Mukhopadhyay A, Ngerng WJ, Chew MY, Sim TB, Kuan WS, Mahadevan M, Lim TK (2014) IDSA/ATS minor criteria aid pre-intensive care unit resuscitation in severe community-acquired pneumonia. Eur Respir J 43:852–862CrossRefGoogle Scholar
  21. 21.
    Salih W, Schembri S, Chalmers JD (2014) Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data. Eur Respir J 43:842–851CrossRefGoogle Scholar
  22. 22.
    Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, Ramirez JA, Christiansen KJ, Waterer GW, Pierce RJ, Armstrong JG, Korman TM, Holmes P, Obrosky DS, Peyrani P, Johnson B, Hooy M, Grayson ML (2008) SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 47:375–384CrossRefGoogle Scholar
  23. 23.
    Ebrahimi F, Giaglis S, Hahn S, Blum CA, Baumgartner C, Kutz A, van Breda SV, Mueller B, Schuetz P, Christ-Crain M, Hasler P (2018) Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial. Eur Respir J 51:1701389CrossRefGoogle Scholar
  24. 24.
    Mendez R, Menendez R, Cilloniz C, Amara-Elori I, Amaro R, Gonzalez P, Posadas T, Gimeno A, Espana PP, Almirall J, Torres A (2018) Initial inflammatory profile in community-acquired pneumonia depends on time since onset of symptoms. Am J Respir Crit Care Med 198:370–378CrossRefGoogle Scholar
  25. 25.
    Singanayagam A, Chalmers JD (2013) Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia. Lancet Respir Med 1:653–662CrossRefGoogle Scholar
  26. 26.
    Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72CrossRefGoogle Scholar
  27. 27.
    Webb BJ, Dascomb K, Stenehjem E, Dean N (2015) Predicting risk of drug-resistant organisms in pneumonia: moving beyond the HCAP model. Respir Med 109:1–10CrossRefGoogle Scholar
  28. 28.
    Hariri G, Tankovic J, Boelle PY, Dubee V, Leblanc G, Pichereau C, Bourcier S, Bige N, Baudel JL, Galbois A, Ait-Oufella H, Maury E (2017) Are third-generation cephalosporins unavoidable for empirical therapy of community-acquired pneumonia in adult patients who require ICU admission? A retrospective study. Ann Intensive Care 7:35CrossRefGoogle Scholar
  29. 29.
    Rodrigo-Troyano A, Sibila O (2017) The respiratory threat posed by multidrug resistant Gram-negative bacteria. Respirology (Carlton, Vic) 22:1288–1299CrossRefGoogle Scholar
  30. 30.
    Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I, Yagi T, Tanikawa Y, Sugino Y, Shindoh J, Ogasawara T, Nomura F, Saka H, Yamamoto M, Taniguchi H, Suzuki R, Saito H, Kawamura T, Hasegawa Y (2013) Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 188:985–995CrossRefGoogle Scholar
  31. 31.
    Maruyama T, Fujisawa T, Ishida T, Ito A, Oyamada Y, Fujimoto K, Yoshida M, Maeda H, Miyashita N, Nagai H, Imamura Y, Shime N, Suzuki S, Amishima M, Higa F, Kobayashi H, Suga S, Tsutsui K, Kohno S, Brito V, Niederman MS (2018) A therapeutic strategy for all pneumonia patients: a 3-year prospective multicenter- cohort study using risk factors for multidrug resistant pathogens to select initial empiric therapy. Clin Infect DisGoogle Scholar
  32. 32.
    Ishida T, Ito A, Washio Y, Yamazaki A, Noyama M, Tokioka F, Arita M (2017) Risk factors for drug-resistant pathogens in immunocompetent patients with pneumonia: evaluation of PES pathogens. J Infect Chemother 23:23–28CrossRefGoogle Scholar
  33. 33.
    Torres A, Cilloniz C, Ferrer M, Gabarrus A, Polverino E, Villegas S, Marco F, Mensa J, Menendez R, Niederman M (2015) Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. Eur Respir J 45:1353–1363CrossRefGoogle Scholar
  34. 34.
    Restrepo MI, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, Faverio P, Cilloniz C, Rodriguez-Cintron W, Aliberti S (2018) Burdenand risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J 52:1701190CrossRefGoogle Scholar
  35. 35.
    Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, Soni NJ, Restrepo MI (2016) Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect Dis 16:1364–1376CrossRefGoogle Scholar
  36. 36.
    Martin-Loeches I, Schultz MJ, Vincent JL, Alvarez-Lerma F, Bos LD, Sole-Violan J, Torres A, Rodriguez A (2017) Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Med 43:48–58CrossRefGoogle Scholar
  37. 37.
    Piralla A, Rovida F, Girello A, Premoli M, Mojoli F, Belliato M, Braschi A, Iotti G, Pariani E, Bubba L, Zanetti AR, Baldanti F (2017) Frequency of respiratory virus infections and next-generation analysis of influenza A/H1N1pdm09 dynamics in the lower respiratory tract of patients admitted to the ICU. PLoS ONE 12:e0178926CrossRefGoogle Scholar
  38. 38.
    Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ (2014) Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 132:Cd008965Google Scholar
  39. 39.
    Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ (2014) Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348:g2545CrossRefGoogle Scholar
  40. 40.
    Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T (2014) Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348:g2547CrossRefGoogle Scholar
  41. 41.
    Dobson J, Whitley RJ, Pocock S, Monto AS (2015) Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet (London, England) 385:1729–1737CrossRefGoogle Scholar
  42. 42.
    Lackenby A, Besselaar TG, Daniels RS, Fry A, Gregory V, Gubareva LV, Huang W, Hurt AC, Leang SK, Lee RTC, Lo J, Lollis L, Maurer-Stroh S, Odagiri T, Pereyaslov D, Takashita E, Wang D, Zhang W, Meijer A (2018) Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017. Antiviral Res 157:38–46CrossRefGoogle Scholar
  43. 43.
    Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, Gabarrus A, Sellares J, Restrepo MI, Anzueto A, Niederman MS, Agusti C (2015) Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313:677–686CrossRefGoogle Scholar
  44. 44.
    Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M (2017) Corticosteroids for pneumonia. Cochrane Database Syst Rev 12:Cd007720Google Scholar
  45. 45.
    Mc Mahon A, Martin-Loeches I (2017) The pharmacological management of severe influenza infection—’existing and emerging therapies’. Expert Rev Clin Pharmacol 10:81–95CrossRefGoogle Scholar
  46. 46.
    Moreno G, Rodriguez A, Reyes LF, Gomez J, Sole-Violan J, Diaz E, Bodi M, Trefler S, Guardiola J, Yebenes JC, Soriano A, Garnacho-Montero J, Socias L, Del Valle Ortiz M, Correig E, Marin-Corral J, Vallverdu-Vidal M, Restrepo MI, Torres A, Martin-Loeches I (2018) Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med 44:1470–1482CrossRefGoogle Scholar
  47. 47.
    Martin-Loeches I, Soares M, Torres A (2016) Neces-SARI-ly? Intensive Care Med 42:928–930CrossRefGoogle Scholar
  48. 48.
    Marty FM, Vidal-Puigserver J, Clark C, Gupta SK, Merino E, Garot D, Chapman MJ, Jacobs F, Rodriguez-Noriega E, Husa P, Shortino D, Watson HA, Yates PJ, Peppercorn AF (2017) Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med 5:135–146CrossRefGoogle Scholar
  49. 49.
    Murphy TF (2008) Placebo-controlled trials of treatments for community-acquired pneumonia: review of the literature and discussion of feasibility and potential value. Clin Infect Dis 47(Suppl 3):S145–S149CrossRefGoogle Scholar
  50. 50.
    Kmietowicz Z (2014) Critics attack chief medical officer’s advice to use antivirals for flu. BMJ 348:g1496CrossRefGoogle Scholar
  51. 51.
    Leroy O, Saux P, Bedos JP, Caulin E (2005) Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 128:172–183CrossRefGoogle Scholar
  52. 52.
    Ferrer M, Travierso C, Cilloniz C, Gabarrus A, Ranzani OT, Polverino E, Liapikou A, Blasi F, Torres A (2018) Severe community-acquired pneumonia: characteristics and prognostic factors in ventilated and non-ventilated patients. PLoS ONE 13:e0191721CrossRefGoogle Scholar
  53. 53.
    De la Calle C, Ternavasio-de la Vega HG, Morata L, Marco F, Cardozo C, Garcia-Vidal C, Del Rio A, Cilloniz C, Torres A, Martinez JA, Mensa J, Soriano A (2018) Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: a propensity score analysis. J Infect 76:342–347CrossRefGoogle Scholar
  54. 54.
    Garin N, Genne D, Carballo S, Chuard C, Eich G, Hugli O, Lamy O, Nendaz M, Petignat PA, Perneger T, Rutschmann O, Seravalli L, Harbarth S, Perrier A (2014) beta-Lactam monotherapy vs. beta-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Internal Med 174:1894–1901CrossRefGoogle Scholar
  55. 55.
    Anderson R, Steel HC, Cockeran R, Smith AM, von Gottberg A, de Gouveia L, Brink A, Klugman KP, Mitchell TJ, Feldman C (2007) Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae. J Antimicrob Chemother 59:224–229CrossRefGoogle Scholar
  56. 56.
    Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE (2015) Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372:1114–1125CrossRefGoogle Scholar
  57. 57.
    Gershengorn HB, Keene A, Dzierba AL, Wunsch H (2015) The association of antibiotic treatment regimen and hospital mortality in patients hospitalized with Legionella pneumonia. Clin Infect Dis 60:e66–e79CrossRefGoogle Scholar
  58. 58.
    Griffin AT, Peyrani P, Wiemken TL, Ramirez JA, Arnold FW (2013) Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia. Infection 41:517–523CrossRefGoogle Scholar
  59. 59.
    Gillet Y, Vanhems P, Lina G, Bes M, Vandenesch F, Floret D, Etienne J (2007) Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 45:315–321CrossRefGoogle Scholar
  60. 60.
    Sicot N, Khanafer N, Meyssonnier V, Dumitrescu O, Tristan A, Bes M, Lina G, Vandenesch F, Vanhems P, Etienne J, Gillet Y (2013) Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia–results of a prospective observational study. Clin Microb Infect 19:E142–E148CrossRefGoogle Scholar
  61. 61.
    File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley I, Thye D (2010) Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 51:1395–1405CrossRefGoogle Scholar
  62. 62.
    Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL (2018) Effect of piperacillin-tazobactam vs. meropenem on 30-day mortality for patients with e coli or klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA 320:984–994CrossRefGoogle Scholar
  63. 63.
    Walden AP, Clarke GM, McKechnie S, Hutton P, Gordon AC, Rello J, Chiche JD, Stueber F, Garrard CS, Hinds CJ (2014) Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. Crit Care 18:R58CrossRefGoogle Scholar
  64. 64.
    Hadfield J, Bennett L (2018) Determining best outcomes from community-acquired pneumonia and how to achieve them. Respirology (Carlton, Vic) 23:138–147CrossRefGoogle Scholar
  65. 65.
    Siow WT, Koay ES, Lee CK, Lee HK, Ong V, Ngerng WJ, Lim HF, Tan A, Tang JW, Phua J (2016) The use of polymerase chain reaction amplification for the detection of viruses and bacteria in severe community-acquired pneumonia. Respir Int Rev Thorac Dis 92:286–294Google Scholar
  66. 66.
    Seymour CW, Kahn JM, Martin-Gill C, Callaway CW, Yealy DM, Scales D, Angus DC (2017) Delays from first medical contact to antibiotic administration for sepsis. Crit Care Med 45:759–765CrossRefGoogle Scholar
  67. 67.
    Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377CrossRefGoogle Scholar
  68. 68.
    Howell MD, Davis AM (2018) Management of ARDS in adults. JAMA 319:711–712CrossRefGoogle Scholar
  69. 69.
    Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, Billot L, Correa M, Glass P, Harward M, Joyce C, Li Q, McArthur C, Perner A, Rhodes A, Thompson K, Webb S, Myburgh J (2018) Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 378:797–808CrossRefGoogle Scholar
  70. 70.
    Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, Timsit JF, Misset B, Ali Benali M, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, Francois B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Bohe J, Loriferne JF, Amathieu R, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Maxime V, Bellissant E (2018) Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 378:809–818CrossRefGoogle Scholar
  71. 71.
    Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124CrossRefGoogle Scholar
  72. 72.
    Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaud P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871CrossRefGoogle Scholar
  73. 73.
    Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, Bogatsch H, Briegel J, Engel C, Gerlach H, Goldmann A, Kuhn SO, Huter L, Meier-Hellmann A, Nierhaus A, Kluge S, Lehmke J, Loeffler M, Oppert M, Resener K, Schadler D, Schuerholz T, Simon P, Weiler N, Weyland A, Reinhart K, Brunkhorst FM, SepNet-Critical Care Trials G (2016) Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA 316:1775–1785CrossRefGoogle Scholar
  74. 74.
    Gibbison B, Lopez-Lopez JA, Higgins JP, Miller T, Angelini GD, Lightman SL, Annane D (2017) Corticosteroids in septic shock: a systematic review and network meta-analysis. Crit Care 21:78CrossRefGoogle Scholar
  75. 75.
    Cheng M, Pan ZY, Yang J, Gao YD (2014) Corticosteroid therapy for severe community-acquired pneumonia: a meta-analysis. Respir Care 59:557–563CrossRefGoogle Scholar
  76. 76.
    Briel M, Spoorenberg SMC, Snijders D, Torres A, Fernandez-Serrano S, Meduri GU, Gabarrus A, Blum CA, Confalonieri M, Kasenda B, Siemieniuk RAC, Boersma W, Bos WJW, Christ-Crain M (2018) Corticosteroids in Patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis. Clin Infect Dis 66:346–354CrossRefGoogle Scholar
  77. 77.
    Wu WF, Fang Q, He GJ (2018) Efficacy of corticosteroid treatment for severe community-acquired pneumonia: a meta-analysis. Am J Emerg Med 36:179–184CrossRefGoogle Scholar
  78. 78.
    Siempos II, Vardakas KZ, Kopterides P, Falagas ME (2008) Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 62:661–668CrossRefGoogle Scholar
  79. 79.
    Nie W, Zhang Y, Cheng J, Xiu Q (2012) Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS ONE 7:e47926CrossRefGoogle Scholar
  80. 80.
    Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, Alexander PE, Fei Y, Vandvik PO, Loeb M, Guyatt GH (2015) Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 163:519–528CrossRefGoogle Scholar
  81. 81.
    Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, Higa F, Takahashi H, Yoshida M, Kohno S, Kaneko T (2015) Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: systematic review and meta-analysis 2015 update. Sci Rep 5:14061CrossRefGoogle Scholar
  82. 82.
    Marti C, Grosgurin O, Harbarth S, Combescure C, Abbas M, Rutschmann O, Perrier A, Garin N (2015) Adjunctive corticotherapy for community acquired pneumonia: a systematic review and meta-analysis. PLoS ONE 10:e0144032CrossRefGoogle Scholar
  83. 83.
    Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC (2016) Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest 149:209–219CrossRefGoogle Scholar
  84. 84.
    Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS (2016) Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 3:Cd010406Google Scholar
  85. 85.
    Sibila O, Rodrigo-Troyano A, Torres A (2016) Nonantibiotic adjunctive therapies for community-acquired pneumonia (corticosteroids and beyond): where are we with them? Semin Respir Crit Care Med 37:913–922CrossRefGoogle Scholar
  86. 86.
    Iannini PB, Paladino JA, Lavin B, Singer ME, Schentag JJ (2007) A case series of macrolide treatment failures in community acquired pneumonia. J Chemother (Florence, Italy) 19:536–545CrossRefGoogle Scholar
  87. 87.
    Cilloniz C, Albert RK, Liapikou A, Gabarrus A, Rangel E, Bello S, Marco F, Mensa J, Torres A (2015) The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia. Am J Respir Crit Care Med 191:1265–1272CrossRefGoogle Scholar
  88. 88.
    Yin YD, Wang R, Zhuo C, Wang H, Wang MG, Xie CM, She DY, Yuan X, Wang RT, Cao B, Liu YN (2017) Macrolide-resistant Mycoplasma pneumoniae prevalence and clinical aspects in adult patients with community-acquired pneumonia in China: a prospective multicenter surveillance study. J Thorac Dis 9:3774–3781CrossRefGoogle Scholar
  89. 89.
    Mendes RE, Farrell DJ, Flamm RK, Talbot GH, Ivezic-Schoenfeld Z, Paukner S, Sader HS (2016) In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the united states. Antimicrob Agents Chemother 60:4407–4411CrossRefGoogle Scholar
  90. 90.
    Pfaller MA, Sader HS, Rhomberg PR, Flamm RK (2017) In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother 61:AAC-02609Google Scholar
  91. 91.
    Donald BJ, Surani S, Deol HS, Mbadugha UJ, Udeani G (2017) Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy. Drug Des Dev Ther 11:3559–3566CrossRefGoogle Scholar
  92. 92.
    Liu Y, Zhang Y, Wu J, Zhu D, Sun S, Zhao L, Wang X, Liu H, Ren Z, Wang C, Xiu Q, Xiao Z, Cao Z, Cui S, Yang H, Liang Y, Chen P, Lv Y, Hu C, Lv X, Liu S, Kuang J, Li J, Wang D, Chang L (2017) A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia. J Microbiol Immunol Infect Wei mian yu gan ran za zhi 50:811–820Google Scholar
  93. 93.
    Amalakuhan B, Echevarria KL, Restrepo MI (2017) Managing community acquired pneumonia in the elderly—the next generation of pharmacotherapy on the horizon. Expert Opin Pharmacother 18:1039–1048CrossRefGoogle Scholar
  94. 94.
    Carreno JJ, Lodise TP (2014) Ceftaroline fosamil for the treatment of community-acquired pneumonia: from FOCUS to CAPTURE. Infect Dis Ther 3:123–132CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Antoni Torres
    • 1
    • 2
    • 3
    Email author
  • James D. Chalmers
    • 4
  • Charles S. Dela Cruz
    • 5
  • Cristina Dominedò
    • 6
  • Marin Kollef
    • 7
  • Ignacio Martin-Loeches
    • 3
    • 8
  • Michael Niederman
    • 9
  • Richard G. Wunderink
    • 10
  1. 1.Department of Pulmonary MedicineHospital Clinic of BarcelonaBarcelonaSpain
  2. 2.August Pi i Sunyer Biomedical Research Institute, IDIBAPSUniversity of BarcelonaBarcelonaSpain
  3. 3.Biomedical Research Networking Centres in Respiratory Diseases (Ciberes)BarcelonaSpain
  4. 4.Division of Molecular and Clinical MedicineUniversity of DundeeDundeeUK
  5. 5.Section of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine and Microbial Pathogenesis, Center of Pulmonary Infection Research and TreatmentYale University School of MedicineNew HavenUSA
  6. 6.Department of Anesthesiology and Intensive Care Medicine, Fondazione Policlinico Universitario A. GemelliUniversità Cattolica del Sacro CuoreRomeItaly
  7. 7.Division of Pulmonary and Critical Care MedicineBarnes-Jewish HospitalSt. LouisUSA
  8. 8.St. James’s Hospital, Multidisciplinary Intensive Care Research Organization (MICRO)DublinIreland
  9. 9.Weill Cornell Medical College and New York Presbyterian/Weill Cornell Medical CenterNew York CityUSA
  10. 10.Pulmonary and Critical Care DivisionNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations